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A B S T R A C T
Purpose
To evaluate the efficacy of the addition of palifosfamide to carboplatin and etoposide in extensive
stage (ES) small-cell lung cancer (SCLC).
Patients and Methods
MATISSEwas a randomized, open-label, adaptive phase III study. Previously untreated patients with
ES SCLC were randomly assigned in a 1:1 fashion to receive carboplatin at area under the serum
concentration-time curve 5 on day 1 plus etoposide 100 mg/m2 per day on days 1 to 3 every 21 days
(CE) or carboplatin at area under the serum concentration-time curve 4 on day 1 plus etoposide
100 mg/m2 per day plus palifosfamide 130 mg/m2 per day on days 1 to 3 every 21 days (PaCE). The
primary end point was overall survival.
Results
In all, 188 patients were enrolled; 94 patients received CE and 94 patients received PaCE. The
median age on both arms was 61 years. Six cycles of chemotherapy were completed on both arms
of the study by approximately 50% of the patients. Serious adverse events were documented and
did not differ significantly between patients receiving PaCE and those receiving CE. Median
overall survival was similar between both armswith 10.03months on PaCE and 10.37months on CE
(P = .096).
Conclusion
The addition of palifosfamide to CE failed to improve survival in ES SCLC.
J Clin Oncol 35:2619-2623. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Platinum doublet chemotherapy has been the
standard of care first-line regimen in patients with
extensive stage (ES) small-cell lung cancer (SCLC)
for the last three decades.1 Cisplatin in combi-
nation with irinotecan is the more frequently used
regimen in Japan, but cisplatin with etoposide or
carboplatin with etoposide (CE) is used in the
United States.2 Objective response rates in the
first-line setting are 67% to 80%, and median
overall survival (OS) is 8 to 13 months.3 Un-
fortunately, disease relapse occurs in all patients,
and second-line chemotherapy options lead to
short responses.4 Novel first-line therapies con-
tinue to be urgently needed.
A previous Hoosier Oncology Group phase
III study demonstrated an improvement in OS
with the addition of ifosfamide to cisplatin and
etoposide.5,6 Ifosfamide, an alkylating agent, in
combination with cisplatin and etoposide (VIP)
increased median OS to 9 months compared with
7.3 months with cisplatin and etoposide alone. In
addition, the 2-year OS was improved from 5%
to 13% in favor of VIP. However, the increased
toxicity and inconvenience of the addition of
ifosfamide, including the need for hospitalization
and intravenous fluids, precluded the adoption
of VIP as the standard first-line regimen for the
treatment of ES SCLC. Ifosfamide is a prodrug
whose cytotoxic effects are largely exerted by its
active metabolite isophosphoramide mustard.6
However, the clinical utility of ifosfamide is
limited by a number of toxic metabolites such
as acrolein and chloracetaldehyde, which are as-
sociated with hemorrhagic cystitis and neuro-
toxicity, respectively.
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Palifosfamide (Zymafos, ZIO-201; ZIOPHARM Oncology,
Boston, MA) is a salt formulation of isophosphoramide mustard,
the active metabolite of ifosfamide that was developed by ZIO-
PHARM Oncology.7,8 Preclinical activity demonstrated that pal-
ifosfamide was active in a number of tumor models, including
sarcoma and lung cancer.9 Palifosfamide was previously combined
with CE in a phase I trial in patients with advanced solid malig-
nancies.10 Carboplatin at an area under the serum concentration-
time curve (AUC) 4 on day 1 combinedwith etoposide at 100mg/m2
on days 1 to 3 and palifosfamide at 100, 130, or 150mg/m2 on days 1
to 3 were evaluated for safety in a standard 3 + 3 dose-escalation
design. The dose-limiting toxicity reported was febrile neutropenia.
Carboplatin at an AUC of 4 on day 1, etoposide at 100 mg/m2 on
days 1 to 3, and palifosfamide at 130 mg/m2 on days 1 to 3 was
shown to be a safe combination. By using that dosing schedule, we
conducted a trial that evaluated the addition of palifosfamide to CE
in patients with untreated ES SCLC.
PATIENTS AND METHODS
Eligible patients had histologic or cytologic diagnosis of ES SCLC defined
as disease beyond the ipsilateral hemithorax, including contralateral
mediastinum in the supraclavicular area and malignant pleural or peri-
cardial effusion or hematogenous spread. Eligibility criteria included
Eastern Cooperative Oncology Group performance status (ECOG PS) of
0 to 2. No prior chemotherapy or radiotherapy was allowed except prior
radiotherapy for brain metastases as long as the patient had recovered
from all acute radiation-related toxicities. Adequate bone marrow (hemo-
globin $ 10.0 g/dL, absolute neutrophil count $ 1,500/mL, platelet count
$ 100,000/mL), liver (total bilirubin# 1.53 upper limit of normal, ALTand
AST# 2.53 upper limit of normal or# 5 if documented liver metastases),
and renal function (estimated glomerular filtration rate $ 60 mL/min per
1.73 m2) were required. Patients were defined as active smokers if they had
smoked 100 cigarettes in their lifetime and continue to smoke, former
smokers if they currently do not smoke, and never smokers if they have never
smoked or have smoked fewer than 100 cigarettes in their entire lifetime.
Patients were excluded if they had significant concurrent medical conditions
that would impact the safety of the patient or if they had a clinically sig-
nificant infection within 7 days of random assignment. In addition, patients
were excluded if they had symptomatic, untreated brain metastases but were
allowed if their brain metastases were asymptomatic. Each patient signed an
institutional review board–approved, protocol-specific informed consent in
accordance with institutional guidelines (Fig 1).
Study Treatments
A minimum of four and maximum of six cycles were allowed on the
trial. The use of growth factors such as erythropoietin or granulocyte
colony-stimulating factor was allowed at the discretion of the investigator.
Carboplatin was administered at AUC 4 on day 1, etoposide at 100 mg/m2
on days 1 to 3, and palifosfamide at 130mg/m2 on days 1 to 3 every 21 days.
Study design and statistical considerations. MATISSE (Multicenter
Adaptive Trial Investigating Small Cell Lung Cancer Survival Endpoints)
was a multicenter, multinational, randomized, controlled, open-label
phase III trial with an adaptive design. The primary end point of the
study was OS defined as the time from random assignment to the date of
death. Initial secondary end points included progression-free survival
(PFS), objective response rates, duration of response, and safety, including
all adverse events (AEs). Tumor-related end points were to be assessed
according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
The study used an adaptive group sequential design that allowed early
stopping for efficacy or futility and sample size re-estimation on the basis of
the results of the interim analysis. The original sample size was estimated
on the basis of 8.4- and 11.2-month median survivals for the control and
treatment arms, respectively. Eligible patients were stratified according to
age, sex, and ECOG PS and were allocated to treatment in a 1:1 ratio. With
one-sided 2.5% type I error and an O’Brien-Fleming boundary at 0.5 for
early efficacy, the power of the trial was 87%. Proportional hazards as-
sumptions were checked by using the Schoenfeld method. On the basis of
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Fig 1. CONSORT diagram. CE, carboplatin and etoposide;
PaCE, palifosfamide plus CE.
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the number of events required, the expected number of patients to be
enrolled on the study was 464 with a maximum number of 548 patients
(274 per arm). The interim analysis by an independent data monitoring
committee was planned after 125 OS events. The intention-to-treat
population was defined as all randomly assigned patients. The safety
population was defined as all randomly assigned patients who were treated
with any study therapy. Patients were randomly assigned in a 1:1 ratio by
using an interactive response system and were stratified on the basis of age,
sex, and initial PS.
The development plans for palifosfamide changed after analysis
showed negative phase III data regarding the addition of palifosfamide
to doxorubicin in metastatic soft tissue sarcomas.11,12 This led to an
amendment that closed the study to enrollment after 188 patients of
the planned 464 patients were randomly assigned. The primary ob-
jective remained OS. The secondary objectives were amended to in-
clude serious AEs (SAEs) only as compared with all AEs. An event was
considered an SAE if it resulted in death, was life-threatening, required
in-patient hospitalization or prolongation of existing hospitalization,
was a persistent or significant disability/incapacity, or was a congenital
anomaly/birth defect. Treatment-emergent adverse events (TEAEs)
were reported and defined AEs that started on or after the date of the
first dose of any study drug. The maximum intensity of events was
recorded by using the National Cancer Institute Common Termi-
nology Criteria for Adverse Events 4.03. The investigator determined
the potential relationship of events to the study drugs. In addition, as
part of the amendment, response assessments and PFS were no longer
required. The amended statistical post hoc power was 80% and a two-
sided 0.05 type I error was used to detect a 0.64 hazard ratio (HR) in
OS with 94 patients on each treatment arm observed for up to
40 months.
RESULTS
Patient Characteristics
This study was a multicenter, multinational study that en-
rolled patients in 13 countries and 70 (of 109) study sites. From
June 8, 2012, through April 22, 2013, 188 patients were randomly
assigned (94 per arm). Among the 188 patients randomly assigned,
there were 159 deaths; 29 patients were alive at the time of this
analysis. The last patient follow-up was performed on December 2,
2014. Baseline characteristics of patients are summarized in Table 1
with no major differences between arms. Median age on both arms
was 61 years, with 70% of patients being males as is expected in
SCLC. Two thirds of patients were treated outside the United States
with Russia enrolling the most patients outside the United States,
followed by Ukraine and France. Sixty patients were treated in the
United States, five in Australia, 14 in Canada, 15 in France, one in
Germany, three in Hungary, and five each in Israel, Italy, and
Poland, 45 in Russia, three in Taiwan, 17 in Ukraine, and 10 in the
United Kingdom (for a list of all study sites, see Appendix Table A1
[online only]). All 188 patients were evaluable for OS and were
included in the intention-to-treat population. Because of the
amendment, response assessments were left to the discretion of
investigators and were collected in only 45% of patients on each
treatment arm.
Treatment Delivered
Approximately half the patients on each arm received six
cycles of chemotherapy. The main reason for death was disease
progression in 82% of patients on either the CE or PaCE arm.
Dose delays and reductions were not collected from enrolling
sites.
Toxicity
The safety population included 92 patients on the PaCE arm
and 91 patients on the CE arm; five patients were not evaluable for
toxicity. Safety population patients had received at least one dose of
the study therapy. There were no significant differences between
the two treatment arms in the number of patients who experienced
SAEs (P. .99). Twenty-six patients (28.3%) on the PaCE arm and
25 patients (27.5%) on the CE arm had at least one SAE as defined
per protocol. SAEs reported in three or more patients on either arm
are listed in Table 2. Approximately 20% of patients on both
treatment arms experienced at least one TEAE. Dizziness was the
Table 1. Demographic and Clinical Characteristics
Characteristic
PaCE
(n = 94)
CE
(n = 94)
No. % No. %
Median age, years (range) 61 (42-82) 61 (32-88)
Sex
Male 66 70 66 70
Female 28 30 28 30
ECOG PS
0 24 25 21 22
1 60 64 62 66
2 10 11 9 10
Metastases
Liver 39 42 37 39
Brain 14 15 17 18
Bone 14 15 16 17
Country
US 31 33 29 31
Other 63 67 65 69
Smoking status
Current 46 49 44 47
Former 36 38 33 35
Unknown 7 7.4 10 10.6
Never 5 5.3 7 7.4
Abbreviations: CE, carboplatin and etoposide; ECOG PS, Eastern Cooperative
Oncology Group performance status; PaCE, palifosfamide plus CE.
Table 2. SAEs Reported in Three or More patients on Each Arm
Toxicity
PaCE
(n = 92)
CE
(n = 91)
No. % No. %
Hematologic
Febrile neutropenia 4 4.3 5 5.5
Pancytopenia 4 4.3 0 0
Neutropenia 1 1.1 3 3.3
Nausea 3 3.3 1 1.1
Dehydration 3 3.3 2 2.2
Hyponatremia 0 0 3 3.3
Dyspnea 3 3.3 2 2.2
Infection 5 5.4 9 9.9
Abbreviation: CE, carboplatin and etoposide; PaCE, palifosfamide plus CE; SAE,
serious adverse event.
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only statistically significant TEAE in both treatment arms and was
noted in 11% of patients on the CE arm compared with 3.3% of
patients on the PaCE arm (P = .048).
Efficacy
The median OS for the PaCE patients was 10.03 months (95%
CI, 7.7 to 10.5 months) compared with 10.37 months (95% CI, 8.7
to 13.4 months) for the CE patients (P = .096). The HR of 1.30
(95%CI, 0.95 to 1.78) is shown in Figure 2. Themedian OS follow-
up was 10.7 months overall and 18.2 months for those 29 patients
who were alive at the last assessment. There were no statistically
significant differences in OS with PaCE versus CE patients according
to age, sex, ECOG PS, or region of treatment except for patients age
65 years or older receiving CEwho had a superior survival compared
with those receiving PaCE (9.7 v 6.8 months; P = .044). Results are
presented in the forest plot in Figure 3.
DISCUSSION
This randomized, controlled, open-label trial with an adaptive
design failed to meet its primary end point of improving OS with
the addition of palifosfamide to CE in patients with ES SCLC. The
median OS with the addition of palifosfamide (PaCE) was nu-
merically inferior to that observed on the CE arm. The addition of
palifosfamide was not associated with an increase in SAEs; how-
ever, with the lack of documentation for all AEs, dose delays, or
dose reductions on our study, it is difficult to make firm con-
clusions regarding the overall toxicity of PaCE compared with CE.
The study did not meet its accrual goal and was underpowered, but
it is extremely unlikely that this would have been a positive study
with full accrual. Carboplatin was given at a lower dose on the
PaCE arm because this was found to be the safe dose in the phase I
study, and it is unlikely that this lower dose had an impact on OS
with the PaCE regimen. This study failed to confirm or reproduce
the small improvement in OS observed on the Hoosier Oncology
Group study that tested the addition of ifosfamide to CE.5 Further
chemotherapy strategies are being evaluated in the first-line setting
of ES SCLC, but it remains unknown whether any will improve
outcomes over platinum doublet chemotherapy. Other strate-
gies being evaluated in the maintenance setting after platinum
doublet therapy in ES SCLC include maintenance sunitinib, which
improved PFS by 1.5 months but not OS.13 In addition, pem-
brolizumab and nivolumab (humanized antibodies targeting the
programmed cell death-1 [PD-1] receptor) are undergoing eval-
uation in the maintenance setting. In addition, PD-1 inhibitors are
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Fig 2. Kaplan-Meier curves for overall survival for intention-to-treat population.
CE, carboplatin and etoposide; PaCE, palifosfamide plus CE.
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Non-US 128 (68.1) 1.276
0.953 to 1.777
0.76 to 1.695
1.151 to 3.177
0.945 to 1.98
0.664 to 2.114
0.969 to 1.894
0.339 to 2.067
0.785 to 2.371
0.875 to 1.862
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Hazard RatioSubgroup
No. (%)
of
Patients
Point
Estimate 95% CI
Fig 3. Forest plot of overall and subgroup hazard ratios including interactions. ECOG PS, Eastern Cooperative Oncology Group performance status.
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being combined with CE in the first-line setting in patients with
limited-stage disease and also in the second-line setting.14
Our understanding of the biology of SCLC has significantly
increased, but translating that knowledge into new clinical ther-
apeutic options that have an impact on the care of patients with
SCLC has yet to be achieved. SCLC has a high mutational burden
resulting from decades of exposure to tobacco-induced carcino-
gens. A panel of several genes seems to be mutated or abnormal in
almost all SCLCs, including p53, retinoblastoma gene, and Myc
family gene members.14,15 In addition, Nfib overexpression has
been shown to accelerate tumorigenesis and promote metastases in
SCLC. ASCL1 is a transcription factor that is pivotal for neuro-
endocrine differentiation and contributes to proliferation and
migration of SCLC.16 Targeting the abnormalities identified and
assessing whether these approaches are effective in SCLC still need
to be evaluated. Chemotherapy remains the only systemic therapy
that has been shown to improve survival in ES SCLC compared
with targeted therapies. Better first- and second-line treatment
options for ES SCLC are necessary to transform the landscape of
this bleak disease.
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Appendix
Table A1. Sites for the MATISSE (Multicenter Adaptive Trial Investigating Small Cell Lung Cancer Survival Endpoints) Study
Country/State/Province City Institution
United States
Alabama Birmingham Birmingham Hematology and Oncology Associates
California Los Angeles University of Southern California
Santa Rosa Redwood Regional Oncology Group
Delaware Newark Christiana Care Health Services
Florida Jacksonville Baptist Cancer Institute
Port St. Lucie Hematology Oncology Associates of the Treasure Coast
Georgia Atlanta Peachtree Hematology Oncology Consultants
Illinois Chicago Rush University Medical Center
Galesburg Medical and Surgical Specialists
Niles Illinois Cancer Specialists
Indiana Fishers Central Indiana Cancer Centers
Goshen Goshen Center for Cancer Care
Indianapolis Indiana University
Lafayette Horizon Oncology Center
Muncie Indiana University Health Ball Memorial Hospital
Kansas Overland Park University of Kansas Hospital
Kentucky Lexington Central Baptist Hospital
Louisiana Baton Rouge Medical Oncology
Maryland Frederick Frederick Memorial Hospital Regional Cancer Therapy Center
Michigan Wyoming Metro Health Cancer Center
Minnesota Duluth Saint Mary’s Medical Center
Minneapolis Virginia Piper Cancer Institute
New Jersey Hackensack John Theurer Cancer Center at Hackensack University Medical
Center
Morristown Hematology Oncology Associates of Northern New Jersey;
Carol G. Simon Cancer Center
New Mexico Albuquerque University of New Mexico Cancer Center
New York Albany New York Oncology Hematology
New York City Montefiore Medical Center
Ohio Cincinnati The Christ Hospital
Dayton Greater Dayton Cancer Center, Medical Oncology Hematology
Associates
Pennsylvania Kingston Medical Oncology Associates of Wyoming Valley
South Carolina Charleston Charleston Hematology Oncology Associates
Texas Dallas Texas Oncology-Medical City Dallas
Dallas Texas Oncology-Baylor, Charles A. Sammons Cancer Center
Galveston University of Texas Medical Branch at Galveston
Houston Oncology Consultants
Wichita Falls Texas Oncology
Vermont Burlington University of Vermont Medical Center
Virginia Fairfax Fairfax Northern Virginia Hematology-Oncology
Washington Seattle Swedish Medical Center
Wisconsin Madison Wisconsin Institutes for Medical Research
Australia
New South Wales Wollongong Southern Medical Day Oncology Care Centre
Canada
Manitoba Winnipeg CancerCare Manitoba
Ontario Oshawa R.S. McLaughlin Durham Regional Cancer Center at Lakeridge
Health Oshawa
Quebec Sainte-Foy Hoˆpital Laval
France
Normandie Caen Centre François Baclesse
Bretagne Brest Centre Hospitalier Universitaire-Hoˆpital Morvan
Centre-Val de Loire Tours Centre Hospitalier Universitaire, Hopital Bretonneau
Lorraine Limoges Hoˆpital du Cluzeau
Pays de la Loire Saint-Herblain Institut de Cance´rologie de l’Ouest-Rene´ Gauducheau
Cote d’Azur-Corse Marseille Hoˆpital Saint Joseph
Rhoˆne -Alpes Pierre Be´nite´ Centre Hospitalier Lyon Sud
Strasbourg Centre Paul Strauss
(continued on following page)
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Table A1. Sites for the MATISSE (Multicenter Adaptive Trial Investigating Small Cell Lung Cancer Survival Endpoints) Study (continued)
Country/State/Province City Institution
Hungary
Hajdu-bihar Debrecen Debreceni Egyetem Orvos e´s Ege´szse´gtudoma´nyi Centrum
Heves Ma´traha´za Ma´trai Gyo´gyinte´zet
Israel Haifa Rambam Medical Center
Jerusalem Hadassah Medical Organization, Ein Kerem
Kfar Saba Meir Hospital Sapir Medical Center
Nahariya Western Galilee Medical Center
Petah Tiqwa Rabin Medical Center, Beilinson Campus
Italy Genova Istituto Nazionale per la Ricerca sul Cancro
Milano Azienda Ospedaliera Ospedale Niguarda Ca’ Granda
Trento Presidio Ospedaliero S. Chiara
Poland
Mazowieckie Warszawa Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie w
Warszawie
Pomorskie Gdansk Uniwersyteckie Centrum Kliniczne
Pomorskie Gdansk Wojewo´dzkie Centrum Onkologii
Zachodniopomorskie Szczecin Specjalistyczny Szpital im. Alfreda Sokolowskiego
Russian Federation
Bashkortostan Ufa Republic Clinical Oncology Dispensary of the Ministry of
Healthcare of Republic of Bashkortostan
Moscow Region Moscow City Oncology Hospital # 62
Primorsky Arkhangelsk State Institution of Healthcare “Arkhangelsk Regional Clinical
Oncology Dispensary”
Tatarstan Kazan Republican Clinical Oncologic Dispensary of Ministry of Health
of Republic Tatarstan
Chelaybinsk State Budget Institution of Healthcare “Chelyabinsk Regional
Clinical Oncology Dispensary”
Ivanovo Ivanovo Regional Oncology Centre
Moscow Cancer Research Center n.a. N.N. Blokhin
Nizhny Novgorod Nizhnij Novgorod City Oncology Dispensary
St. Petersburg State Educational Institution “S.M. Kirov Military Medical
Academy of Ministry of Defense of Russia”
St. Petersburg St. Petersburg State I.P. Pavlov Medical University
Yaroslavl State Healthcare Institution of Yaroslavl region “Regional
Clinical Oncologic Hospital”
Taiwan Taichung China Medical University Hospital
United Kingdom Manchester Wythenshawe Hospital
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